{"entity":{"id":"nct06607627","kind":"trial","name":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","aka":[],"tldr":"A phase 3 trial of Gefurulimab in childhood cancers, run by Alexion Pharmaceuticals, Inc., now recruiting.","summary":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis is a phase 3 interventional study registered as NCT06607627 by Alexion Pharmaceuticals, Inc., with 12 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-15. Interventions recorded: Gefurulimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06607627","url":"https://clinicaltrials.gov/study/NCT06607627"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06607627","phase":"3","setting":"An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)","sponsor":"Alexion Pharmaceuticals, Inc.","enrolled":12,"outcomes":[]},"route":"/trials/nct06607627/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}